GAMMA Investing LLC Buys 94,464 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

GAMMA Investing LLC increased its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 17,558.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 95,002 shares of the specialty pharmaceutical company's stock after purchasing an additional 94,464 shares during the quarter. GAMMA Investing LLC owned approximately 0.44% of ANI Pharmaceuticals worth $6,360,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ANIP. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of ANI Pharmaceuticals by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock worth $582,000 after buying an additional 364 shares in the last quarter. Natixis Advisors LLC lifted its position in shares of ANI Pharmaceuticals by 2.3% in the 4th quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company's stock worth $1,028,000 after purchasing an additional 417 shares during the period. US Bancorp DE boosted its position in ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after acquiring an additional 531 shares during the last quarter. KBC Group NV increased its holdings in ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after purchasing an additional 600 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its stake in ANI Pharmaceuticals by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 11,397 shares of the specialty pharmaceutical company's stock worth $630,000 after acquiring an additional 675 shares in the last quarter. Institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Stock Down 0.5%

Shares of ANIP stock traded down $0.31 on Tuesday, hitting $62.87. The stock had a trading volume of 262,045 shares, compared to its average volume of 308,700. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The business has a 50 day moving average of $65.05 and a 200 day moving average of $61.00. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $77.00. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of -114.31 and a beta of 0.55.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm had revenue of $197.12 million during the quarter, compared to analyst estimates of $179.75 million. During the same quarter last year, the business posted $0.82 EPS. The company's revenue for the quarter was up 43.4% on a year-over-year basis. As a group, analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Insider Buying and Selling

In other ANI Pharmaceuticals news, insider Christopher Mutz sold 4,000 shares of the business's stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total value of $241,800.00. Following the sale, the insider now directly owns 107,317 shares in the company, valued at $6,487,312.65. The trade was a 3.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Meredith Cook sold 400 shares of the business's stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $68.96, for a total value of $27,584.00. Following the completion of the sale, the vice president now owns 80,145 shares in the company, valued at $5,526,799.20. This represents a 0.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,681 shares of company stock worth $347,638. 11.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

ANIP has been the subject of a number of research analyst reports. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 target price for the company. Wall Street Zen lowered ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. Jefferies Financial Group assumed coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a "buy" rating and a $80.00 price target for the company. Guggenheim restated a "buy" rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. Finally, HC Wainwright reissued a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $80.13.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.